PGNY

Progyny Inc

Add to Watchlist

Advanced Chart

22.940

+0.94(4.273%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

22.990

Open

22.240

VWAP

22.68

Vol

916.20K

Mkt Cap

1.97B

Low

21.9767

Amount

20.78M

EV/EBITDA(TTM)

21.26

Total Shares

95.22M

1.63B

EV/OCF(TTM)

8.02

P/S(TTM)

1.70

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

295.11M

-1.11%

0.360

-14.29%

291.92M

+1.85%

0.367

-8.13%

316.51M

+4.08%

0.410

-4.65%

Estimates Revision

The market is revising Upward the revenue expectations for Progyny, Inc. (PGNY) for FY2025, with the revenue forecasts being adjusted by 1.45% over the past three months. During the same period, the stock price has changed by 7.35%.

Revenue Estimates for FY2025

Revise Upward

+1.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.52%

In Past 3 Month

Stock Price

Go Up

+7.35%

In Past 3 Month

6 Analyst Rating

18.79% Upside

Wall Street analysts forecast PGNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGNY is 27.25 USD with a low forecast of 21.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

4 Hold

0 Sell

Moderate Buy

18.79% Upside

Current: 22.940

Low

21.00

Averages

27.25

High

30.00

18.79% Upside

Current: 22.940

Low

21.00

Averages

27.25

High

30.00

Truist

Jailendra Singh

Hold

maintain

$24 -> $27

2025-07-17

New

Reason

Truist

Jailendra Singh

Price Target

$24 -> $27

2025-07-17

New

maintain

Hold

Reason

Truist analyst Jailendra Singh raised the firm's price target on Progyny to $27 from $24 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Health Care IT / Digital Health sector names. Despite the strong YTD outperformance in shares, investor sentiment still remains relatively mixed, with the interest level from long-onlies/generalist investors seen as "relatively selective", the analyst tells investors in a research note. HCIT space has also benefited from the lack of direct tariff exposure and other macro uncertainty as well as renewed capital market activity, the firm added.

Leerink

Market Perform -> Outperform

upgrade

2025-07-08

Reason

Leerink

Price Target

2025-07-08

upgrade

Market Perform -> Outperform

Reason

Leerink upgraded Progyny to Outperform from Market Perform.

Leerink

Market Perform

Outperform

upgrade

$28

2025-07-08

Reason

Leerink

Price Target

$28

2025-07-08

upgrade

Market Perform

Outperform

Reason

Leerink upgraded Progyny to Outperform from Market Perform with an unchanged price target of $28, calling Progyny's second positive pre-announcement in six months "yet another signal that membership activity has rebounded from last year's lows." While the firm had previously been "cautiously optimistic" that Q1 results were the start of a trend but, today's data "gives us a bit more comfort" in becoming more constructive, the analyst tells investors.

Canaccord

Hold

downgrade

$23 -> $21

2025-05-12

Reason

Canaccord

Price Target

$23 -> $21

2025-05-12

downgrade

Hold

Reason

Canaccord lowered the firm's price target on Progyny PGNY) to $21 from $23 and keeps a Hold rating on the shares. The firm said they posted a second consecutive quarter of solid results to kick off 2025, well ahead of Canaccord and consensus estimates. The extended services offered to certain Amazon (AMZN) members contributed roughly $2 million more than contemplated in guidance provided last quarter.

BTIG

David Larsen

Hold

Strong Buy

Upgrades

$28

2025-03-31

Reason

BTIG

David Larsen

Price Target

$28

2025-03-31

Upgrades

Hold

Strong Buy

Reason

BTIG analyst David Larsen upgraded Progyny to Buy from Neutral with a $28 price target.

Canaccord Genuity

Richard Close

Hold

Maintains

$17 → $23

2025-02-28

Reason

Canaccord Genuity

Richard Close

Price Target

$17 → $23

2025-02-28

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Progyny Inc (PGNY.O) is 13.40, compared to its 5-year average forward P/E of 123.93. For a more detailed relative valuation and DCF analysis to assess Progyny Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

123.93

Current PE

13.40

Overvalued PE

308.44

Undervalued PE

-60.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

26.89

Current EV/EBITDA

8.55

Overvalued EV/EBITDA

45.70

Undervalued EV/EBITDA

8.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

4.05

Current PS

1.57

Overvalued PS

6.34

Undervalued PS

1.77

Financials

Annual

Quarterly

FY2025Q1

YoY :

+16.53%

324.04M

Total Revenue

FY2025Q1

YoY :

+30.49%

24.17M

Operating Profit

FY2025Q1

YoY :

-10.88%

15.06M

Net Income after Tax

FY2025Q1

YoY :

0.00%

0.17

EPS - Diluted

FY2025Q1

YoY :

+88.75%

46.97M

Free Cash Flow

FY2025Q1

YoY :

+4.23%

23.39

Gross Profit Margin - %

FY2025Q1

YoY :

-6.00%

16.14

FCF Margin - %

FY2025Q1

YoY :

-23.52%

4.65

Net Margin - %

FY2025Q1

YoY :

-17.80%

10.11

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

59.0K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

5.2M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

6.9K

Volume

6-9

Months

166.7K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

8.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

59.0K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

5.2M

USD

Months

0-12

0.0

USD

Months

PGNY News & Events

Events Timeline

2025-07-10 (ET)

2025-07-10

09:13:32

Progyny partners with OURA in wearable tech data

2025-07-08 (ET)

2025-07-08

08:29:13

Progyny sees Q2 results 'slightly better than' guidance ranges on Q1 call

2025-07-08

08:28:02

Progyny enters revolving credit facility for up to $200M

News

4.0

07-17Benzinga

Truist Securities Maintains Hold on Progyny, Raises Price Target to $27

2.0

07-09NASDAQ.COM

Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?

4.0

07-08Benzinga

Leerink Partners Upgrades Progyny to Outperform, Announces $28 Price Target

People Also Watch

GDYN

Grid Dynamics Holdings Inc

Akero Therapeutics Inc

Silicon Motion Technology Corp

Tarsus Pharmaceuticals Inc

Companhia Paranaense de Energia

Golden Ocean Group Ltd

Oxford Lane Capital Corp

3.870

USD

-2.52%

FAQ

What is Progyny Inc (PGNY) stock price today?

The current price of PGNY is 22.94 USD — it has increased 4.27 % in the last trading day.

PGNY

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PGNY News & Events

Events Timeline

News

People Also Watch

FAQ

What is Progyny Inc (PGNY) stock price today?

What is Progyny Inc (PGNY)'s business?

What is the price predicton of PGNY Stock?

What is Progyny Inc (PGNY)'s revenue for the last quarter?

What is Progyny Inc (PGNY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Progyny Inc (PGNY)'s fundamentals?

How many employees does Progyny Inc (PGNY). have?

What is Progyny Inc (PGNY) market cap?